Relationship Between Genes Important in Blood Pressure Regulation and Blood Pressure Therapy in Hypertension
Assessment of the Relationship Between Genes That Encode Proteins Important in Blood Pressure Regulation and Blood Pressure Therapy in Patients With Hypertension
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
2.1 Study Design and Protocol Overview This is a post-hoc association study of patients who have been diagnosed with high blood pressure and have been stable on medication treatment for at least 6 months. The purpose of this study is to evaluate the relationship between optimal medication therapy (or the therapy that has resulted in the most stable blood pressure for that particular patient) and the predicted optimal medication therapy based on a patient's genetic profile.
Chart reviews for the patient's history of antihypertensive therapy will be coupled with buccal swabs and blood pressure readings collected from eligible patients who have provided informed consent. The swab will be analyzed for fourteen genetic variants that are associated with antihypertensive therapy response (efficacy, side-effects).
2.2 Study Objective To assess the relationship between the drug therapy class/combination of therapy classes that resulted in the best blood pressure control for a patient vs. what the Geneticure high blood pressure panel would have predicted.
2.3 Secondary Objectives
- To assess the clinical time to achieve optimal blood pressure treatment.
- To assess the number of office visits required to achieve optimal blood pressure treatment.
Tipo di studio
Iscrizione (Effettivo)
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Subject is able and willing to provide informed consent
- Subject is ≥ 30 and ≤ 70 years of age
- Subject with diagnosis of Hypertension for a minimum of 1 year
- Subject has been on the same class/classes of blood pressure medication for a minimum of 6 months. Note: A change in dosage, frequency, or specific medication is acceptable as long as there have been no changes to the class/classes of medications prescribed.
- Subject with a Body Mass Index (BMI) ≥ 19 and ≤ 35
Subject is currently prescribed and taking one of the following classes of medications alone or in combination with each other or a Ca+ channel blocker.
- Diuretics
- ACE Inhibitors
- Angiotensin Receptor Blocker (ARB)
- Beta-blockers
Exclusion Criteria:
- Subject has clinically significant kidney disease as determined by the investigator.
- Subject has clinically significant cardiac disease as determined by the investigator.
- Subject has clinically significant vascular disease as determined by the investigator.
- Subject has a diagnosis of secondary hypertension or is experiencing a complication of pregnancy.
- Subject is currently prescribed and taking any additional class of medication(s) for high blood pressure not included in the list above, with the exception of a Ca+ channel blocker.
- Subject has Systolic BP > 190 or Diastolic BP > 120 documented within the six months prior to visit.
- Subject has a regular alcohol intake of greater than 21 units per week in the past 6 months
- Subject has smoked greater than two packs of cigarettes (total) or equivalent nicotine intake in the past 6 months.
- Subject has an anticipated survival less than 12 months.
- Any other reason that the subject is inappropriate for study enrollment in the opinion of the Investigator.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Ambulatory blood pressure changes (using sphygmomanometry) in response to therapy according to genes important in blood pressure regulation
Lasso di tempo: one year
|
To assess the relationship between the drug therapy class/combination of therapy classes that resulted in the best blood pressure control for a patient vs. what the Geneticure high blood pressure panel would have predicted.
We will assess blood pressure values (systolic and diastolic blood pressure, in mmHg) at rest in patients on different blood pressure medications.
|
one year
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
The clinical time to achieve optimal blood pressure treatment
Lasso di tempo: One year
|
One year
|
|
The number of office visits required to achieve optimal blood pressure treatment.
Lasso di tempo: One year
|
One year
|
Collaboratori e investigatori
Sponsor
Investigatori
- Direttore dello studio: Krista Kleve, RCRI
Pubblicazioni e link utili
Pubblicazioni generali
- Johnson MW, Sprissler R, Olson TP, Beenken GW, Snyder EM. Multi-Gene Pharmacogenetics and Blood Pressure Control in Patients with Hypertension. The FASEB Journal 30:942.1. 2016
- Johnson MW, Sprissler R, Olson TP, Beenken GW, Snyder EM. Time to Blood Pressure Control According to Drug Class in Patients with Hypertension. The FASEB Journal 30:941.12. 2016.
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- GTC01
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .